Events & Presentations

Events & Updates

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Presentations
Date Title
05/22/2017
Archived Events
Date Event Details
09/08/2017
1:30 PM
BioCentury NewsMakers In The BioTech Industry Conference
Speaker: Rachel King, CEO
06/07/2017
2:00 PM ET
Jefferies 2017 Global Healthcare Conference
Speaker: Rachel King, CEO
03/22/2017
GlycoMimetics CFO Brian Hahn Testifies Before House Capital Markets Subcommittee

Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc., provided testimony on March 22 on behalf of the Biotechnology Innovation Organization (BIO) before the House Subcommittee on Capital Markets and Government Sponsored Enterprises. Hahn serves as the Co-Chair of BIO’s Finance & Tax Committee. Read the full press release at  http://www.businesswire.com/news/home/20170322006085/en/

03/07/2017
10:00 AM ET
Cowen and Company 37th Annual Health Care Conference
Speaker: Rachel King, CEO
12/05/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 4049-Poster Session, A Phase I/II Study of GMI¬1271, a Novel E¬Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date
12/05/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 3826-Poster Session, E¬Selectin Antagonist GMI¬1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Absrtact 2823-Poster Session, Vascular E-Selectin Protects Leukemia Cells from Chemotherapy By Directly Activating Pro-Survival NF-Kb Signaling - Therapeutic Blockade of E-Selectin Dampens NF-Kb Activation
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 3519-Poster Session, Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograph Murine Model
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 2826-Poster Session, dministration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML
12/04/2016
6:00 PM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract 2509-Poster Session, Rivipansel (GMI-1070) Inhibits E-Selectin Recognition of Sialyl LewisX Activation and Arrest of Human Neutrophils Expressed on CD62L (L-selectin) and Blocks Integrin
12/04/2016
7:30 AM PT
58th Annual American Society of Hematology (ASH) Meeting
Speaker: Abstract #270-Rivipansel, A Small Pan-Selecting Antagonist Improves Cerebral Perfusion and Inhibits Leukocyte Adhesion and in Murine Sickle Cell Disease Model
11/17/2016
1:20 PM
Jefferies 2016 London Healthcare Conference
Speaker: Rachel King, CEO
11/15/2016
4:30 PM
Stifel 2016 Healthcare Conference
Speaker: Rachel King, CEO
11/11/2016
12:00 PM ET
Society for Immunotherapy of Cancer Meeting
Speaker: Abstract 209
09/08/2016
Glycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care

Today, GlycoMimetics joins leading patient advocacy groups, researchers, clinicians, policymakers, industry, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research both in the United States and globally. The newly formed Sickle Cell Disease Coalition’s first order of business is an international call to action to change the status quo of SCD. 

Click here for more information

08/11/2016
2:30 PM ET
Canaccord Genuity 36th Annual Growth Conference
Add to Briefcase = add file to Briefcase